Quick Answer
Transcode Therapeutics, Inc. reported Research And Development Expense of $9.71 million for the year ending 2024.
- Transcode Therapeutics, Inc. showed a decrease of -20.9% in Research And Development Expense from 2023 to 2024.
- This data is from Transcode Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on April 15, 2025.
- XBRL data for this metric is available from 2020 to 2024 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: $75.0 thousand | Q3 2020: $53.9 thousand | Q1 2021: $263.8 thousand | Q2 2021: $211.8 thousand | Q3 2021: $992.9 thousand | Q1 2022: $1.88 million | Q2 2022: $2.62 million | Q3 2022: $3.04 million | Q1 2023: $2.59 million | Q2 2023: $2.97 million | Q3 2023: $3.34 million | Q1 2024: $1.76 million | Q2 2024: $3.08 million | Q3 2024: $1.23 million | Q1 2025: $2.22 million | Q2 2025: $2.57 million | Q3 2025: $3.16 million.
- Over the full 5 years of available data (2020 to 2024), Transcode Therapeutics, Inc.'s Research And Development Expense has grown by 3,312.2%.
- Historical annual values: Fiscal year 2024: $9.71 million | Fiscal year 2023: $12.26 million | Fiscal year 2022: $10.23 million | Fiscal year 2021: $2.75 million | Fiscal year 2020: $284.5 thousand.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: